Specific glycine to alanine mutation eliminates dynamic interaction of polymeric GlyT1a N-terminus with Coomassie Brilliant Blue G-250

Facile synthesis of biopolymer decorated magnetic coreshells for enhanced removal of xenobiotic azo dyes through experimental modelling

Since contamination of xenobiotics in water bodies has become a global issue, their removal is gaining ample attention lately. In the present study, nZVI was synthesized using chitosan for removal of two such xenobitic dyes, Bromocresol green and (BCG) and Brilliant blue (BB), which have high prevalence in freshwater and wastewater matrices. nZVI functionalization prevents nanoparticle aggregation and oxidation, enhancing the removal of BCG and BB with an efficiency of 84.96% and 86.21%, respectively. XRD, FESEM, EDS, and FTIR have been employed to investigate the morphology, elemental composition, and functional groups of chitosan-modified nanoscale-zerovalent iron (CS@nZVI). RSM-CCD model was utilized to assess the combined effect of five independent variables and determine the best condition for maximum dye removal. The interactions between adsorbent dose (2-4 mg), pH (4-8), time (20-40 min), temperature (35-65 0C), and initial dye concentration (40-60 mg/L) was modeled to study the response, i.e., dye removal percentage. The reaction fitted well with Langmuir isotherm and pseudo-first-order kinetics, with a maximum qe value of 426.97 and 452.4 mg/g for BCG and BB, respectively. Thermodynamic analysis revealed the adsorption was spontaneous, and endothermic in nature. Moreover, CS@nZVI could be used up to five cycles of dye removal with remarkable potential for real water samples.

Lateral flow immunoassay for furazolidone point-of-care testing: Cater to the call of saving time, labor, and cost by coomassie brilliant blue labeling

Furazolidone (FZD) and its metabolite called 3-amino-2-oxazolidinone (AOZ) would induce carcinogenic and mutagenic effects to human. In this work, to develop a novel, stable, and simple point of care testing (POCT) with a potential to social applied for FZD detection, we utilized the aspect of protein staining of coomassie brilliant blue (CBB) to exploit a new CBB-LFIA strategy free of NPs. Only one mixing step is needed during the probe manufacturing process, which requires just 2 h and is a great time saving strategy compared with other methods (requiring 4-33 h for probe preparation). Besides, the cost of CBB-LFIA is 300 times lesser than other LFIA with respect to obtaining the label. The developed CBB-LFIA was successfully applied to detect AOZ with a detection limit of 2 ng mL^-1, without any influence from other potential interfering compounds. The proposed CBB-LFIA exhibited prominent practical application, and possesses considerable utilization potential in the related field.

Phosphorylation of Serine 157 Protects the Rat Glycine Transporter GlyT2 from Calpain Cleavage

The N-terminal region of the rat glycine transporter 2 (rGlyT2, SLC6A5) is cleaved by calpain protease in vitro, which raises the question of its protection against calpain in vivo. Here, we used a phosphomimetic and orthogonal phosphoserine translation approach to investigate the possible role of phosphorylation in the protection of two calpain cleavage sites, M156/S157 and G164/T165, previously identified in the N-terminus region of the rat GlyT2. Replacement of serine 157 with phosphomimetic aspartate or with orthogonal phosphoserine blocked both calpain cleavage sites and caused an electrophoretic mobility shift of rGlyT2N fusion proteins. Both effects can be reversed by dephosphorylation, suggesting that phosphorylation might induce structural changes in the rGlyT2 N-terminus, preventing the accessibility of the M156/S157 and G164/T165 cleavage sites to calpain in vivo. In comparison with the wild type, the phosphomimetic mutation S157D increased the total immunoreactivity of the transporter expressed in neuroblastoma cells, suggesting that serine 157 phosphorylation or phosphorylation-regulated calpain cleavage might contribute to the turnover of the glycine transporter GlyT2.